Total Valuation
GeneOne Life Science, Inc. has a market cap or net worth of ₩48.51B. The enterprise value is ―.
Market Cap₩48.51B
Enterprise Value―
Share Statistics
GeneOne Life Science, Inc. has 18,176,582 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,176,582
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
GeneOne Life Science, Inc.’s return on equity (ROE) is -1.17 and return on invested capital (ROIC) is -55.99%.
Return on Equity (ROE)-1.17
Return on Assets (ROA)-0.40
Return on Invested Capital (ROIC)-55.99%
Return on Capital Employed (ROCE)-0.65
Revenue Per Employee520.24M
Profits Per Employee-1.04B
Employee Count46
Asset Turnover0.20
Inventory Turnover3.38
Valuation Ratios
The current PE Ratio of GeneOne Life Science, Inc. is ―. GeneOne Life Science, Inc.’s PEG ratio is 0.08.
PE Ratio―
PS Ratio1.40
PB Ratio0.82
Price to Fair Value0.82
Price to FCF-2.02
Price to Operating Cash Flow-2.92
PEG Ratio0.08
Income Statement
In the last 12 months, GeneOne Life Science, Inc. had revenue of 23.93B and earned -47.66B in profits. Earnings per share was -13.95K.
Revenue23.93B
Gross Profit-21.43B
Operating Income-42.42B
Pretax Income-47.57B
Net Income-47.66B
EBITDA-28.60B
Earnings Per Share (EPS)-13.95K
Cash Flow
In the last 12 months, operating cash flow was -15.88B and capital expenditures -34.44M, giving a free cash flow of -15.91B billion.
Operating Cash Flow-15.88B
Free Cash Flow-15.91B
Free Cash Flow per Share-875.50
Dividends & Yields
GeneOne Life Science, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.05
52-Week Price Change-76.93%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)158.84K
Important Dates
GeneOne Life Science, Inc. upcoming earnings date is Aug 18, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
GeneOne Life Science, Inc. as a current ratio of 0.36, with Debt / Equity ratio of 66.76%
Current Ratio0.36
Quick Ratio0.11
Debt to Market Cap0.87
Net Debt to EBITDA-1.11
Interest Coverage Ratio-17.87
Taxes
In the past 12 months, GeneOne Life Science, Inc. has paid 87.41M in taxes.
Income Tax87.41M
Effective Tax Rate>-0.01
Enterprise Valuation
GeneOne Life Science, Inc. EV to EBITDA ratio is -2.28, with an EV/FCF ratio of -3.93.
EV to Sales2.72
EV to EBITDA-2.28
EV to Free Cash Flow-3.93
EV to Operating Cash Flow-3.94
Balance Sheet
GeneOne Life Science, Inc. has ₩6.82B in cash and marketable securities with ₩34.15B in debt, giving a net cash position of -₩27.33B billion.
Cash & Marketable Securities₩6.82B
Total Debt₩34.15B
Net Cash-₩27.33B
Net Cash Per Share-₩1.50K
Tangible Book Value Per Share₩11.91K
Margins
Gross margin is -79.36%, with operating margin of -177.27%, and net profit margin of -199.16%.
Gross Margin-79.36%
Operating Margin-177.27%
Pretax Margin-198.80%
Net Profit Margin-199.16%
EBITDA Margin-119.51%
EBIT Margin-195.55%
Analyst Forecast
The average price target for GeneOne Life Science, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-53.96%
EPS Growth Forecast10.26%